

26th May 2016

To,

1. National Stock Exchange of India
Exchange Plaza, 5th Floor, Plot no. C/1, G Block
Bandra Kurla Complex, Bandra (East)
Mumbai – 400 051
2. BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

**Sub.: Receipt of ANDA approval from US FDA
(Scrip Codes: NSE – AJANTPHARM EQ & BSE – AJANTPHARM
532331)**

Dear Sir/Madam,

We are pleased to inform you that we have received the ANDA approval for Voriconazole Tablets from US FDA.

Press release issued by us for the same is enclosed for your information and records.

Thanking You,

Yours faithfully,



Gaurang Shah
Sr. GM – Legal & Company Secretary

Encl.: Press Release

Press Release**Ajanta Pharma Announces US FDA approval of Voriconazole Tablets**

Mumbai, India – (26th May, 2016) - Ajanta Pharma Limited, (Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331), today announced the receipt of final approval for Voriconazole Tablets (50mg & 200mg), from the U.S. Food and Drug Administration (FDA). Voriconazole is a triazole antifungal for treatment of serious invasive fungal infections and the generic version of Vfend®¹.

Voriconazole Tablets is part of ever-growing portfolio of products that Ajanta has developed for the U.S. market. To date, the U.S. FDA has granted Ajanta Pharma 10 ANDA final approvals and 2 tentative approvals. An additional 14 ANDAs are under review with FDA.

About Ajanta Pharma

Ajanta Pharma Limited is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.

For more details about Ajanta Pharma Ltd., you may visit us at www.ajantapharma.com.

For Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com.

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

¹ Vfend is a registered trademark of PF PRISM CV.

[Safe Harbour Statement](#)